Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

Blood

Volumn 113, Issue 12, 2009, Pages 2765-2775

  Chetaille, Bruno ^a   Bertucci, François ^a   Finetti, Pascal ^a   Esterni, Benjamin ^a   Stamatoullas, Aspasia ^b,c   Picquenot, Jean Michel ^b,c   Copin, Marie Christine ^c,d   Morschhauser, Frank ^c,d   Casasnovas, Olivier ^c,e   Petrella, Tony ^c,e   Molina, Thierry ^c,f   Vekhoff, Anne ^c,f   Feugier, Pierre ^c,g   Bouabdallah, Reda ^a,c   Birnbaum, Daniel ^a   Olive, Daniel ^a   Xerri, Luc ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c Groupe d'Etude des Lymphomes de l'Adulte (GELA)   (France)

^d CENTRE HOSPITALIER   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BCL 11A PROTEIN; BLEOMYCIN; CD20 ANTIBODY; DACARBAZINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; EPSTEIN BARR VIRUS; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; MOLECULAR DYNAMICS; PD 1 GENE; PDCD1 GENE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; VIRUS INFECTION;

EID: 63849185609     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168096     Document Type: Article

References (49)

1. Ferme C, Mounier N, Casasnovas O, et al. Long- term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006: 107:4636-4642.
2. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2008;141:3-13.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
4. Hoppe RT, Advani RH, Bierman PJ, et al. Hodgkin disease/lymphoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:210-230.
5. Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:1732-1740.
6. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Hodgkin lymphoma. In: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:189-235.
7. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.
8. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA. 2007;104:13134-13139.
9. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
10. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immuno-suppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220-3224.
11. Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol. 2005;206:68-75.
12. Kapatai G, Murray P. Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 2007;60:1342-1349.
13. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173:195-204.
14. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol. 2006;34:399-406.
15. Sup SJ, Alemany CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005;23:3773-3779.
16. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. Topoisomerase Ilalpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res. 2008;14:1759-1766.
17. Natkunam Y, Hsi ED, Aoun P, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood. 2007;109:298-305.
18. Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol. 2007;25:3101-3108.
19. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467-1473.
20. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005;46:1581-1591.
21. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958-965.
22. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193-200.
23. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene. 2002;21:3095-3102.
24. Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al. Spanish Hodgkin Lymphoma Study Group: tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108:662-8.
25. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
26. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
27. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22:1564-1571.
28. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
29. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101:4988-5006.
30. Venables WN, Ripley BD. Modern Applied Statistics with S-Plus, 2nd Ed. Berlin, Germany: Springer; 1987.
31. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-15550.
32. Open Biomedical Ontologies. The Gene Ontology Database. http://www.geneontology.org/. Accessed November 10, 2008.
33. Massachusetts Institute of Technology. Molecular Signatures Database (MSigDB). http://www.broad.mit.edu/gsea/msigdb/index.jsp. Accessed November 10, 2008.
34. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952-4963.
35. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www.ncbi.nlm.nih.gov/geo.Accessed November 10, 2008.
36. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560-1570.
37. Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature. 2006;441:1015-1019.
38. Xerri L, Chetaille B, Seriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39:1050-1058.
39. National Center for Biotechnology Information. Entrez Gene. http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene. Accessed November 10, 2008.
40. Pulford K, Banham AH, Lyne L, et al. The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. Leukemia. 2006;20:1439-1441.
41. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111:3778-3792.
42. Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica. 2007;92:1059-1066.
43. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol. 2004;173:68-78.
44. Weniger MA, Pulford K, Gesk S, et al. Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia. 2006;20:1880-1882.
45. Lim WH, Kireta S, Russ GR, Coates PT. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood. 2007;109:1043-1050.
46. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889-1899.
47. Rüdiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13(suppl 1):44-51.
48. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239-245.
49. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20:17-22.